Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594157 | 1.00 | ABL1 (0.42) | ABL1BRD4AOC3NPY5RPTGS2 | |
| SCHEMBL29594254 | 0.85 | KCNH2 (0.37) | ABL1BRD4NPY5RPTGS2MAPK14 | |
| SCHEMBL28461712 | 0.85 | KCNH2 (0.37) | ABL1BRD4NPY5RPTGS2MAPK14 | |
| SCHEMBL1064834 | 0.84 | HSP90AB1 (0.43) | ABL1AOC3NPY5RMAPK14CYP2D6 | |
| SCHEMBL27826688 | 0.82 | VCP (0.38) | NPY5RPTGS2VCP | |
| SCHEMBL29594273 | 0.82 | VCP (0.38) | NPY5RPTGS2VCP | |
| SCHEMBL29593325 | 0.82 | ABL1 (0.36) | ABL1NPY5RPTGS2KCNH2 | |
| SCHEMBL28470468 | 0.82 | ABL1 (0.36) | ABL1NPY5RPTGS2KCNH2 | |
| SCHEMBL28464519 | 0.80 | PTGS2 (0.37) | ABL1BRD4PTGS2MAPK14 | |
| SCHEMBL29593211 | 0.80 | PTGS2 (0.37) | ABL1BRD4PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |